(Stroke. 1995;26:593-596.)
© 1995 American Heart Association, Inc.
Articles |
From Research and Evaluation, Southern California Kaiser Permanente Medical Care Program, Pasadena (D.B.P.), and the School of Medicine, University of California at San Francisco (H.B.).
| Abstract |
|---|
|
|
|---|
Methods In this nested case-control study, we examined the association of retinopathy with risk of nonembolic ischemic stroke in diabetes. In a cohort of 2124 diabetic persons identified at multiphasic health checkups during the period from 1979 through 1985, 56 suffered a nonembolic ischemic stroke during follow-up, which extended through 1991. For each case subject, one diabetic control subject matched by sex and year of birth was selected from the same cohort of diabetics. Medical records were reviewed to gather information on risk factors for stroke. Information on risk factors was retrieved for 52 of the 56 cases.
Results The estimated relative risk of stroke in diabetic subjects with retinopathy was 2.8 (95% confidence interval, 1.2 to 6.9). After adjustment for age, sex, smoking, use of insulin, average systolic blood pressure, and average random glucose, the estimated relative risk was 4.0 (95% confidence interval, 1.0 to 14.5). The relative risk of stroke in diabetic subjects with retinopathy remained elevated after exclusion of those with complications other than retinopathy.
Conclusions Stroke prevention in diabetic persons is a challenge. Diabetic subjects with retinopathy appear to be a group at particularly high risk of ischemic stroke. Development of preventive interventions might focus on this group.
Key Words: cerebrovascular disorders comparative study diabetes mellitus retinal diseases risk factors
| Introduction |
|---|
|
|
|---|
This nested case-control study sought to examine risk factors for nonembolic ischemic stroke in a defined cohort of diabetic subjects who received multiphasic health checkups (MHC) in two Northern California Kaiser Permanente facilities. The original purpose of the study was to determine the relationship between stroke risk and an index of glycemic control. We found that retinopathy was an independent risk factor for nonembolic ischemic stroke. This relationship seems not to have been previously reported, and it is therefore the focus of this report.
| Methods |
|---|
|
|
|---|
Subjects were identified from the cohort of diabetic persons who had an MHC in either of two Northern California Kaiser Permanente Medical Care Program facilities in the years 1979 through 1985. Persons who stated on a self-administered questionnaire that they were being treated by a doctor for diabetes at the time of the MHC were considered to be diabetic. Potential cases were identified by review of hospitalizations in Kaiser Permanente hospitals in the years 1979 through 1991 for ischemic cerebrovascular disease (International Classification of Diseases, 9th Revision, Clinical Modification codes 433 to 436). For each case subject, one diabetic control subject was selected who was matched on exact year of birth and sex, had an MHC in the same year as the case subject, and was still a member of the Kaiser Permanente Health Plan in the year the case subject was hospitalized. The index date was the date of the hospitalization for the case subject and her or his associated control. The period from the MHC to the hospitalization of the case subject was the index period.
Medical records of case and control subjects were abstracted to verify the diagnosis of diabetes, to establish the diagnosis of first-ever nonembolic ischemic stroke according to predetermined criteria, and to collect information on risk factors for stroke.
Case and control subjects were considered to have verified cases of diabetes if, during the index period, they were treated for diabetes with diet, oral hypoglycemic drugs, or insulin; they had one or more fasting blood glucose measurements >140 mg/dL; or they had two or more postload or random blood glucose measurements >200 mg/dL.
Stroke was defined as the rapid onset of a new neurological deficit lasting more than 24 hours when the deficit was not known to have a noncentral nervous system cause. Excluded were case subjects with a prior history of cerebrovascular disease, those with blood seen on computed tomographic or magnetic resonance imaging scan or blood in lumbar puncture, and those with arterial dissection or venous thrombosis. Cases found in persons with atrial fibrillation, rheumatic heart disease, or another possible cardiac source for embolus were considered probably of cardioembolic origin and were also excluded.
A patient was considered to have neuropathy, nephropathy, retinopathy, peripheral vascular disease, or history of myocardial infarction if there was any mention of these diabetic complications in the medical chart during the index period. All blood glucose values from the beginning of the index period up to, but not including, the index date were recorded. For case subjects, measurements made after the onset of neurological symptoms were not recorded. An index of glucose control was constructed by taking the average of the first of these recorded measurements for each quarter year during the index period. This method for creating an index blood glucose control is an attempt to take into account the tendency of physicians to do more frequent glucose measurements in patients whose diabetes is out of control. Separate averages were computed for fasting and for postload or random blood glucose measurements. All blood pressure measurements during the index period were also recorded, and an index of blood pressure was computed by taking the average of the first blood pressure measurement for each quarter.
Thirty-three percent of subjects had missing data for random and/or average blood glucose. Data on smoking status were also missing for two subjects. Because missing data on any variable for either member of a matched pair caused the pair to be dropped, a matched multivariate analysis resulted in the loss of almost half of all pairs. For this reason, the multivariate analysis was performed unmatched. The results of both matched and unmatched univariate analyses are presented.
For categorical variables, the program STATXACT8 was used to derive exact unmatched maximum likelihood estimates of the odds ratio. The 95% confidence intervals (CIs) presented are mid-probability corrected intervals. Unconditional logistic regression was used in the multivariate analysis and to derive univariate estimates of the odds ratio for continuous variables. Conditional logistic regression was used in the matched analysis. The term "estimated relative risk" (RR) is used as a synonym for odds ratio in the remainder of the article and in the tables.
| Results |
|---|
|
|
|---|
Table 1
shows the characteristics of the 52 case and
control subjects at the time of the baseline MHC and on the index date
and the unadjusted matched and unmatched estimates of the RR of stroke,
according to each characteristic. Conclusions based on the matched and
unmatched analyses were the same. Smokers at baseline had a lower risk
of stroke. Baseline levels of total cholesterol and fasting glucose
were associated with a slightly increased risk of stroke. Among
variables assessed for the index period, hypertension and insulin
treatment were associated with an increased RR of stroke in diabetic
subjects. There was also an association of average random and average
fasting glucose levels with an increased RR of stroke, although the
associations were weak. The RR of stroke was elevated in relation to
each of the diabetic complications. Among the diabetic complications,
the highest RR was observed for myocardial infarction. However, over
40% of stroke case subjects had retinopathy, and the RR of stroke was
significantly increased only in relation to retinopathy.
|
Table 2
shows the estimated RR of ischemic stroke in
diabetic subjects with retinopathy adjusting for various confounding
variables and for variables that are potentially a part of the causal
pathway. The RR for stroke remains elevated in diabetic subjects with
retinopathy after adjusting for age and sex and for other variables
associated with increased risk of stroke. These analyses show that
retinopathy is an independent risk factor for stroke.
|
Table 3
shows the estimated RR of ischemic stroke in
subgroups of diabetic subjects defined by the absence of other diabetic
complications, adjusting first for age and sex and then for these
variables as well as average glucose values and average systolic blood
pressure. The risk of stroke was increased in diabetic subjects with
retinopathy in each of these subgroups, although the CIs are wide in
some subgroups, perhaps in part because of the small number of
subjects.
|
| Discussion |
|---|
|
|
|---|
Our data suggest that retinopathy is a risk factor for nonembolic stroke independent of smoking, blood pressure, and other diabetic complications. The poor quality of our measure of glycemic control does not allow a firm conclusion about independence of the association from this factor. The data suggest that glycemic control may be important.
The study has some limitations. Most important, despite the relatively large size of the diabetic population from which cases were derived, the number of cases was small. We had problems with missing data. Missing data have unpredictable effects on multivariate estimates on risk.
The information on presence or absence of retinopathy was based on notations in medical records. These notations are of uncertain accuracy. It was not possible to distinguish diabetic and hypertensive retinopathy. We believe that retinopathy noted in medical records is probably more severe than what might be observed on systematic examination of the retina. Thus, our results may pertain only to severe retinopathy. Studies that distinguish hypertensive from diabetic retinopathy would be needed to confirm our findings.
Information on duration of diabetes was so incomplete that we could not consider it in the analysis. We also could not distinguish type I and type II diabetic subjects. We were not able to reliably separate lacunar and nonlacunar stroke based on chart review. The number of cases of each type would probably not be large enough for subgroup analysis even if we could separate lacunar from nonlacunar stroke.
Prevention of stroke in diabetes is a challenge. In the Early Treatment Diabetic Retinopathy Study,12 650 mg/d aspirin in diabetic subjects with retinopathy decreased the risk of fatal and nonfatal stroke in type I diabetes (RR, 0.60; 95% CI, 0.18 to 2.04) but slightly increased the risk in mixed diabetes (RR, 1.11; 95% CI, 0.59 to 2.07) and type II diabetes (RR, 1.37; 95% CI, 0.77 to 2.43). In the Veterans Administration Cooperative Study,13 which included diabetic patients who had undergone a lower extremity amputation, stroke was significantly less frequent in patients treated with 75 mg/d dipyridamole plus 325 mg/d aspirin than in those who received placebo. In the European Stroke Prevention Study,14 the benefit of 990 mg/d aspirin plus 225 mg/d dipyridamole in preventing stroke in diabetics with cerebrovascular disease was less than in nondiabetics and failed to achieve statistical significance. In the Ticlopidine Aspirin Stroke Study,15 1300 mg/d aspirin was less effective in preventing stroke in diabetic than in nondiabetic subjects, although 500 mg/d ticlopidine was equally effective.
The data are sparse, but they suggest the hypothesis that low-dose aspirin alone is insufficient to prevent stroke in diabetic subjects, especially those who already have manifestations of microvascular disease. Further elucidation of the mechanisms of ischemic stroke in diabetes and determination of the efficacy of antiplatelet and fibrinolytic agents in preventing stroke in diabetic subjects are priority areas for further research. Because this group appears to be at particularly high risk of stroke, preventive interventions might focus on diabetic persons with retinopathy.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received November 4, 1994; revision received January 19, 1995; accepted January 19, 1995.
| References |
|---|
|
|
|---|
2. Chukwuma C, Tuomilehto J. Diabetes and the risk of stroke. J Diabetes Complications. 1993;7:250-262. [Medline] [Order article via Infotrieve]
3. Biller J, Love BB. Diabetes and stroke. Med Clin North Am. 1993;77:95-109. [Medline] [Order article via Infotrieve]
4. Palumbo PJ, Elveback LR, Whisnant JB. Neurological complications of diabetes mellitus: transient ischemic attack, stroke, and peripheral neuropathy. Adv Neurol. 1978;19:593-601. [Medline] [Order article via Infotrieve]
5. Webster P. The natural history of stroke in diabetic patients. Acta Med Scand. 1980;207:417-424. [Medline] [Order article via Infotrieve]
6. Turnbridge WMG. Factors contributing to deaths of diabetics under fifty years of age. Lancet. 1981;2:569-571. [Medline] [Order article via Infotrieve]
7. Abbott RD, Donahue RP, MacMahon SW, Reed DM, Yunko K. Diabetes and the risk of stroke: the Honolulu Heart Program. JAMA. 1987;949-952.
8. STATXACT, Version 2. Cambridge, Mass: Cytel Software; 1991.
9. Aronson SM. Intercranial vascular lesions in patients with diabetes mellitus. J Neuropathol Exp Neurol. 1973;23:1983-1996.
10. Bell ET. A postmortem study of vascular disease in diabetes. Arch Pathol. 1952;53:444-455.
11.
Alex M, Baron EK, Goldenberg S, Blumenthal HT. An autopsy
study of cerebrovascular accident in diabetes mellitus.
Circulation. 1962;25:663-673.
12.
ETDRS Investigators. Aspirin effects on mortality and
morbidity in patients with diabetes mellitus: early treatment diabetic
retinopathy study, report 14. JAMA. 1992;268:1292-1300.
13. Colvell JA, Bingham SF. The Cooperative Study Group: VA Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene, IV: issues in design, interpretation and analysis. Haemostasis. 1986;16:433-438. [Medline] [Order article via Infotrieve]
14.
Sivenius J, Laakso M, Riekkinen P, Smets P, Lowenthal A.
European Stroke Prevention Study: effectiveness of antiplatelet therapy
in diabetic patients in secondary prevention of stroke.
Stroke. 1992;23:851-854.
15. Grotta J. Is aspirin effective in preventing strokes in diabetic patients? Stroke. 1993;24:760. Letter.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
F N Doubal, P E Hokke, and J M Wardlaw Retinal microvascular abnormalities and stroke: a systematic review J. Neurol. Neurosurg. Psychiatry, February 1, 2009; 80(2): 158 - 165. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Baker, P. J. Hand, J. J. Wang, and T. Y. Wong Retinal Signs and Stroke: Revisiting the Link Between the Eye and Brain Stroke, April 1, 2008; 39(4): 1371 - 1379. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Cheung, S. Rogers, D. J. Couper, R. Klein, A. R. Sharrett, and T. Y. Wong Is Diabetic Retinopathy an Independent Risk Factor For Ischemic Stroke? Stroke, February 1, 2007; 38(2): 398 - 401. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |